Key result
Pathogenic arrhythmia variants are linked to a higher burden of arrhythmia phenotypes versus noncarriers.
Why the study?
It was unclear whether pathogenic or likely pathogenic arrhythmia variants found in individuals without genetic testing indications associate with meaningful phenotypes, while prevalent variants of uncertain significance limit clinical actionability.
Does genome sequencing in a population without indication for arrhythmia genetic testing identify phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes?
Cohort (n=21,846)
Yes
Does genome sequencing in a population without indication for arrhythmia genetic testing identify phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes?
Genome sequencing in unselected populations can identify unrecognized carriers of pathogenic arrhythmia variants who have a higher burden of clinical arrhythmia phenotypes.
Answers are grounded in this paper and cite their sources.
May support population sequencing to identify unrecognized arrhythmia variant carriers; hypothesis-generating and should not yet change practice.
BACKGROUND: Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability. METHODS: The eMERGE-III study (Electronic Medical Records and Genomics Phase III) is a multicenter prospective cohort that included 21 846 participants without previous indication for cardiac genetic testing. Participants were sequenced for 109 Mendelian disease genes, including 10 linked to arrhythmia syndromes. Variant carriers were assessed with electronic health record-derived phenotypes and follow-up clinical examination. Selected variants of uncertain significance (n=50) were characterized in vitro with automated electrophysiology experiments in HEK293 cells. RESULTS: As previously reported, 3.0% of participants had P/LP variants in the 109 genes. Herein, we report 120 participants (0.6%) with P/LP arrhythmia variants. Compared with noncarriers, arrhythmia P/LP carriers had a significantly higher burden of arrhythmia phenotypes in their electronic health records. Fifty-four participants had variant results returned. Nineteen of these 54 participants had inherited arrhythmia syndrome diagnoses (primarily long-QT syndrome), and 12 of these 19 diagnoses were made only after variant results were returned (0.05%). After in vitro functional evaluation of 50 variants of uncertain significance, we reclassified 11 variants: 3 to likely benign and 8 to P/LP. CONCLUSIONS: Genome sequencing in a large population without indication for arrhythmia genetic testing identified phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes. As the genomes of large numbers of people are sequenced, the disease risk from rare variants in arrhythmia genes can be assessed by integrating genomic screening, electronic health record phenotypes, and in vitro functional studies. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier; NCT03394859.
No takes yet. Share an insight, caveat, or question.
Glazer et al. (2021) conducted a cohort in Arrhythmia syndromes (n=21,846). Pathogenic or likely pathogenic (P/LP) arrhythmia variants vs. Noncarriers was evaluated on Burden of arrhythmia phenotypes in electronic health records. Carriers of pathogenic or likely pathogenic arrhythmia variants had a significantly higher burden of arrhythmia phenotypes in their electronic health records compared with noncarriers.
Synapse has enriched 10 related papers. Consider them for comparative context: